Most importantly, preclinical studies suggest that the pharmacological inhibition of PARP not only affects DNA repair but also inhibits CXCL12/CXCR4 signalling, which influences tumour cell migration, reduces metastatic ability, and potentially increases therapeutic response [52]. Here, CXCR4 is linked to neoplasm.